In this session, Elena Stoyanova, PhD (Touchlight) introduces mbDNA™ (Megabulb DNA), a novel single-stranded circular DNA template featuring a customizable stem region and fully user-defined sequence. Chesney Michels, PhD (ElevateBio)…
Read More
MegaBulb DNA: Enabling better non-viral gene therapy with mbDNA – a cell-free circular ssDNA
Read More
Touchlight’s dbDNA™ enables fast, scalable GMP-grade AAV production with fewer impurities and no bacterial sequences, confirmed by nanopore sequencing.
Read More
mbDNA™ is a groundbreaking non-viral gene-editing technology with a unique circular single-stranded DNA design, engineered for high HDR efficiency and enhanced knock-in performance in immune and stem cells. Compatible with…
Read More
CRISPR HDR Breakthrough with mbDNA™: ssDNA Template Boosts Cell Viability & Scalability CRISPR has transformed our ability to edit genomes, enabling targeted insertions, deletions, and base corrections. Yet…
Read More
mbDNA™ is a synthetic, circular single-stranded DNA (ssDNA) vector engineered to overcome the limitations of both viral and non-viral gene-editing templates. By combining a customisable double-stranded stem region with a…
Read More
Touchlight’s circular DNA offerings introduces a suite of innovative architectures, mbDNA™, sscDNA, hsscDNA, and dscDNA, designed to overcome the limitations of traditional gene editing tools. These constructs offer enhanced stability,…
Read More
This video introduces Touchlight’s state-of-the-art DNA manufacturing facility, located in the historic Morelands Waterworks in Hampton. Once a vital site for Victorian London’s clean water supply, it has been transformed…
Read More
In this webinar, Touchlight’s Elena Stoyanova, PhD introduces the company’s innovative DNA manufacturing technologies, focusing on their proprietary dbDNA™ (Doggybone DNA) and the newly developed mbDNA™ (MegaBulb DNA ). She…
Read More
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Read More
